| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | RNA-Based Therapies | Hematologic System |
Recent Updates
Recently added Catalysts
Silence Therapeutics Plc American Depository Share$10.49
-1.34 (-11.53%)
Market Cap
270.65 M
EPS
-1.88
P/E Ratio
-3.04 $
Value Trade
770.86 K
SEC Financials
Q1 2026Dilution Risk
40%Revenue
422.00 K
R&D Expenses
9.12 M
Operating CF
-15.60 M
Total Assets
115.12 M
Total Liabilities
65.72 M
Equity
49.40 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
70.08 M
Monthly Burn
5.20 M
Runway
10.8 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
556.51 K
52 Week Range
2.45 - 7.91
% held by Insiders
15.61 %
% held by Institutions
27.45 %
Enterprise Value
185.70 M
Total Shares
47.23 M
Short %
3.95 %
Float Shares
38.75 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Silence Therapeutics Plc American Depository Share
143Total events
2Upcoming
27Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Management Change
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutdivesiranClinical Data
Subscribe to view catalyst details
TBD
◆Topline ReadoutdivesiranClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-12 | divesiran | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-12 | divesiran | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-12 | divesiran | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
divesiran | polycythemia vera | Phase 1 | 2026-06-11 | In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies.; During the active treatment period, only 5 phlebotomies were required.; During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported.; Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days. Read More | Inquiries: Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communications +1 (646) 637-3208 ir@silence-therapeutics.com Media Relations MKC Strategies Mary Conway +1 (516) 606-6545 mconway@mkcstrategie Read More | |
divesiran | polycythemia vera | Phase 1 | 2026-06-11 | In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies.; During the active treatment period, only 5 phlebotomies were required.; During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported.; Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days. Read More | Inquiries: Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communications +1 (646) 637-3208 ir@silence-therapeutics.com Media Relations MKC Strategies Mary Conway +1 (516) 606-6545 mconway@mkcstrategie Read More | |
divesiran | polycythemia vera | Phase 1 | 2026-06-11 | In the six months prior to treatment, the 21 enrolled patients required a total of 80 phlebotomies.; During the active treatment period, only 5 phlebotomies were required.; During the 16-week follow-up period after the final dose, only 4 phlebotomies were reported.; Among 14 patients with further follow-up data, the median time to first phlebotomy was 287 days. Read More | Inquiries: Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communications +1 (646) 637-3208 ir@silence-therapeutics.com Media Relations MKC Strategies Mary Conway +1 (516) 606-6545 mconway@mkcstrategie Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SLN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SLN
Jun 11, 2026▲ +11.3%on this news
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Silence Therapeutics presented follow-up data on Divesiran at EHA 2026, showcasing its durable efficacy in treating Polycythemia Vera. The data suggests a potential best-in-class profile for the treatment. Further details on the study's outcomes and implications were not provided in the article.
Read more →-SLN
Jun 11, 2026▲ +11.3%on this newsshared move
Inquiries: Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communications +1 (646) 637-3208 ir@silence-therapeutics.com Media Relations MKC Strategies Mary Conway +1 (516) 606-6545 mconway@mkcstrategie
Silence Therapeutics presented promising follow-up data from the Phase 1 SANRECO study for divesiran, an siRNA therapy targeting TMPRSS6 in polycythemia vera patients, at EHA 2026. The data demonstrated significant reductions in phlebotomy requirements and improvements in disease symptoms and quality of life. The ongoing Phase 2 SANRECO study, set for topline results in August 2026, is evaluating dosing regimens. Divesiran is designed to address a critical need in the treatment of polycythemia vera, which currently lacks approved therapies targeting red blood cell production.
Read more →-SLN
May 27, 2026Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
Silence Therapeutics is set to participate in the Jefferies Global Healthcare Conference. This event will provide an opportunity for the company to engage with investors and discuss its strategic initiatives. Details regarding the specific topics to be covered during the conference have not been disclosed.
Read more →-SLN
May 12, 2026▼ -5.3%on this news
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics is set to participate in the H.C. Wainwright BioConnect Investor Conference. This event provides a platform for the company to engage with investors and discuss its advancements in the biopharma sector. Further details regarding the presentation or topics of discussion have not been disclosed.
Read more →-SLN
May 7, 2026▼ -5.6%on this newsshared move
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics plc reported its first quarter 2026 financial results, highlighting a reduced net loss of $15 million compared to $28.5 million in the same period last year. The company is advancing its siRNA therapies, with the Divesiran Phase 2 trial results expected in August 2026. Additionally, the SANRECO Phase 1 study has been accepted for presentation at the EHA 2026 Annual Congress.
Read more →-SLN
May 7, 2026▼ -5.6%on this newsshared move
xfeff; Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for top
Silence Therapeutics reported its first quarter 2026 financial results and highlighted key advancements, including progress on the Phase 2 SANRECO trial of divesiran for polycythemia vera, which is expected to yield topline results by August 2026. The firm has also achieved a notable reduction in R&D expenses compared to the prior year. Financially, the company ended the quarter with $70.1 million in cash and short-term investments, alongside an increase in collaboration revenue with AstraZeneca. Despite these advancements, Silence Therapeutics still faced a substantial net loss during the quarter.
Read more →-SLN
Mar 5, 2026Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Silence Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting the progress of its Phase 2 SANRECO trial for divesiran, an innovative siRNA therapy for polycythemia vera. The trial is on track for topline results in the third quarter of 2026. The company emphasized its strong clinical execution and potential for future growth.
Read more →-SLN
Dec 15, 2025Silence Therapeutics Announces Leadership Changes 15 December 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel
Silence Therapeutics plc has announced the departure of Craig Tooman from his role as President and CEO, effective December 14, 2025. Following his departure, Iain Ross, the current Chairman, will serve as interim leader. The company also plans to appoint an additional US-based Board member while reappointing James Ede Golightly to the Board. The company remains confident in its financial stability and future advancements within its siRNA therapeutic pipeline.
Read more →-SLN
Nov 6, 2025Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong
Silence Therapeutics announced its financial results for Q3 2025, highlighting the full enrollment of its SANRECO Phase 2 study of divesiran for polycythemia vera. The company reported a cash position expected to fund operations into 2028 and anticipates topline results from the study in Q3 2026. Despite a net loss of $21 million, which is an improvement from the same period last year, Silence's management remains optimistic about its pipeline and operational execution.
Read more →-SLN
Oct 23, 2025Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Top
Silence Therapeutics has successfully completed patient enrollment in its SANRECO Phase 2 study of divesiran, a novel siRNA targeting TMPRSS6 for polycythemia vera (PV). The trial, which enrolled 48 participants, aims to evaluate divesiran's efficacy in maintaining hematocrit levels below 45% without the need for phlebotomies. Initial topline results are expected in the third quarter of 2026. The rapid enrollment highlights growing enthusiasm for this first-in-class treatment, which may meet significant unmet medical needs in the PV patient population.
Read more →-SLN
Aug 7, 2025Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in P
Silence Therapeutics has announced its financial results for the second quarter of 2025, highlighting encouraging updates on its SANRECO Phase 1 trial data for divesiran, which is being developed as a first-in-class siRNA therapy for polycythemia vera. The company is on track for full enrollment of the Phase 2 study by the end of the year and retains a cash runway that extends into 2028. However, Silence continues to face challenges with rising net losses and overall financial performance concerns.
Read more →-SLN
May 8, 2025Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Company further extends cash guidance into 2028 8 May 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN ( Silence or the C
Silence Therapeutics has announced its financial results for the first quarter of 2025, reporting a notable increase in net loss despite certain operational successes. The company extended its cash guidance into 2028 and is focused on advancing the SANRECO Phase 2 study of divesiran. However, financial performance shows a significant decline in revenue and an increased loss compared to the same quarter last year. The company continues to implement cost-saving initiatives to maintain its financial health while investing in its clinical programs.
Read more →-SLN
May 6, 2025Silence Therapeutics Welcomes Tim McInerney to Board of Directors Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechn
Silence Therapeutics has appointed Tim McInerney to its Board of Directors, effective immediately. McInerney brings over 30 years of experience in the pharmaceutical industry and healthcare investment banking. His appointment is seen as pivotal for guiding the company's transition into U.S. markets and enhancing its position as a leader in siRNA therapies. Additionally, board member James Ede-Golightly will retire at the upcoming Annual General Meeting in June 2025, marking a significant change in board composition.
Read more →-SLN
Feb 27, 2025Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update The Company s cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GM
Silence Therapeutics plc has reported its financial results for the full year ended December 31, 2024. The company announced an extension of its cash guidance into 2027, reflecting a solid financial position with over $147 million in cash reserves. Silence Therapeutics is prioritizing investment in its pipeline, especially focusing on divesiran for Polycythemia Vera, with full enrollment in its Phase 2 study expected by year-end. However, the initiation of the Phase 3 study for zerlasiran will only proceed once a partnership is established.
Read more →-SLN
Dec 9, 2024▼ -6.2%on this news· ran to -23% by day 3
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting New divesiran data continue to show substantial reduction in phlebotomy freque
Silence Therapeutics presented additional Phase 1 data for divesiran, an siRNA targeting TMPRSS6, at the ASH Annual Meeting. The results demonstrated a significant reduction in phlebotomy frequency and lower hematocrit levels in polycythemia vera patients. The company has now initiated the Phase 2 portion of the SANRECO study after successful Phase 1 trials that showed encouraging safety and efficacy profiles. Divesiran continues to be recognized as a promising first-in-class siRNA treatment for this condition.
Read more →-SLN
Nov 18, 2024▼ -13.2%on this news· ran to -45% by day 1
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 w
Silence Therapeutics presented data from its Phase 2 ALPACAR-360 study on zerlasiran at the AHA Scientific Sessions 2024. This study reports over 80% reduction in Lp(a) levels over 36 weeks with effects persisting up to 60 weeks post-initial administration. The results demonstrate the drug's potential for long-term efficacy with minimal dosing and indicate a path forward for Phase 3 trials targeting a significant patient population affected by elevated Lp(a). The findings have been published in the Journal of the American Medical Association.
Read more →-SLN
Nov 14, 2024▼ -8.3%on this news· ran to -54% by day 3shared move
to this Report on Form 6-K. Our actual results may differ materially from those contained in or implied by the forward-looking statements contained in the following discussion and analysis. Overview Silence Therapeutics
Silence Therapeutics reported significant financial losses in Q3 2024 compared to the same period in 2023. Revenue decreased from £2.8 million to £1.1 million, while gross profit fell to a loss of £1.6 million. The company's operating loss more than doubled, reaching £22.5 million in Q3 2024. The financial statements reveal increasing cumulative losses, raising concerns about the company's operational sustainability.
Read more →-SLN
Jun 27, 2024Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequ
Silence Therapeutics has announced positive results from its SANRECO Phase 1 study of divesiran in patients with polycythemia vera. The treatment successfully eliminated the need for phlebotomy in all well-controlled patients, and the company is poised to advance divesiran into Phase 2 trials. The study, which evaluated 16 patients, showed that divesiran was well tolerated and demonstrated favorable effects on hematological parameters. Silence's CEO noted the results position the company as a significant player in the precision medicine space for blood diseases.
Read more →-SLN
Jun 24, 2024Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration 24 June 2024 LONDON, Silence Therapeutics plc, Nasdaq: SLN ( Silence or the Company ), an experienced and innovative bi
Silence Therapeutics has announced the receipt of a $2 million milestone payment from Hansoh Pharmaceutical Group as part of their ongoing collaboration. This payment marks the achievement of a second undisclosed milestone related to their joint research efforts. The partnership, established in October 2021, aims to develop innovative RNA-based therapies targeting specific genetic diseases using Silence's proprietary mRNAi GOLD platform. This event underscores the progress being made in advancing their pipeline while highlighting potential for significant future financial gains from the collaboration.
Read more →-SLN
Jun 20, 2024Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Da
Silence Therapeutics announced positive topline 48-week data from a Phase 2 study of zerlasiran (SLN360) in patients with elevated lipoprotein(a). The study demonstrated highly significant and sustained reductions in Lp(a) levels, with a median maximum reduction of around 90% observed. Zerlasiran was well tolerated, and the findings support the company’s plan to progress into Phase 3 trials. These results highlight the potential of zerlasiran to address major unmet medical needs in cardiovascular health.
Read more →-SLN
May 16, 2024to this Report on Form 6-K. Our actual results may differ materially from those contained in or implied by any forward-looking statements. Overview Silence Therapeutics plc (“we”, “us”, ȁ
Silence Therapeutics plc reported its financial results for the three months ended March 31, 2024, showing a revenue increase to £12.4 million compared to £11.4 million for the same period the previous year. The company recorded a reduced operating loss of £4.2 million, down from £12.1 million in the prior year, indicating improvement in its financial performance. However, accumulated losses now stand at £305.7 million, highlighting ongoing challenges. The report reiterates the company's commitment to research and development while managing its financial strategy.
Read more →-SLN
May 1, 2024Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors 29 April 2024 LONDON, Silence Therapeutics plc (Nasdaq: SLN) ( Silence or the Company ), an experienced and innovative biotechnology comp
Silence Therapeutics plc announced the retirement of Alistair Gray from its Board of Directors, effective May 1, 2024. Gray has served on the board since 2015, contributing to the company's transformation into a notable player in biotechnology. He expressed his gratitude towards his colleagues and acknowledged the progress made under current leadership. The company continues to develop innovative treatments utilizing RNA interference technology, indicating a forward-looking approach despite the board change.
Read more →-SLN
Apr 15, 2024▼ -6.8%on this news
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this Document, please take advice from a stockbroker, solicitor, accountant or ot
Silence Therapeutics plc has issued an important document addressing shareholders regarding the upcoming Annual General Meeting (AGM) scheduled for May 17, 2024. The document details procedural requirements for shareholders, including proxy voting instructions and the option to attend the meeting remotely via the Lumi Meeting Platform. Additionally, it highlights a cautionary note regarding forward-looking statements and encourages recipients to seek independent professional advice as necessary.
Read more →-SLN
Mar 13, 2024Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a) Study met primary endpoint and demonstrated highly significant reductions in Lp(a
Silence Therapeutics has announced positive topline results from its ongoing ALPACAR-360 phase 2 study of zerlasiran, focusing on patients with elevated lipoprotein(a) levels. The study met its primary endpoint with highly significant Lp(a) reduction, achieving at least a 90% median percentage decrease at week 36. No new safety concerns were observed, and these findings align with phase 1 trial results. The company plans to report 48-week data in the second quarter of 2024.
Read more →-SLN
Feb 23, 2024Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial 23 February 2024 LONDON, Silence Therapeutics plc, Nasdaq: SLN ( Silence or the Company
Silence Therapeutics has received a $10 million milestone payment from AstraZeneca following the initiation of a Phase 1 clinical trial. This milestone is the first under their collaboration aimed at developing therapeutics using Silence's mRNAi GOLD platform. The partnership, which began in March 2020, has the potential for significant future payments based on successful target nominations and development progress. Silence is focused on addressing diseases with unmet medical needs such as cardiovascular and hematological conditions.
Read more →-SLN
Feb 2, 2024SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this Agreement ) is made and entered into as of
Silence Therapeutics plc has entered into a Securities Purchase Agreement with identified investors for the sale of 5,714,286 American Depositary Shares (ADSs). The transaction is structured under the SEC's exemption provisions from securities registration to ensure compliance. Alongside the ADS sale, a Registration Rights Agreement will be executed, granting the investors certain registration rights. This offering reflects investor interest but carries risks regarding market performance and regulatory compliance.
Read more →-SLN
Dec 1, 2023▲ +5.3%on this news
statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-look
Silence Therapeutics has announced key promotions within its executive leadership team, elevating Curtis Rambaran, MD to Chief Medical Officer and Marie Wikström Lindholm, PhD to Chief Scientific Officer. These leadership changes are expected to bolster the company's development of precision-engineered medicines and its mRNAi GOLD platform. Both executives bring substantial experience and expertise that is anticipated to drive the company’s growth and innovation. Current advancements highlight the company's focus on silencing diseases through novel therapeutic approaches.
Read more →-SLN
Nov 1, 2023▲ +29.3%on this news· ran to +51% by day 3
About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thou
Silence Therapeutics announced encouraging topline results from its Phase 1 multiple dose study of zerlasiran, targeting high lipoprotein(a) levels in adults with stable atherosclerotic cardiovascular disease. The study found that zerlasiran achieved reductions in lipoprotein(a) levels of up to 99%, remaining about 90% lower than baseline throughout the treatment period. The drug was well tolerated, and safety concerns were minimal. Upcoming phase 2 results are anticipated to further validate these findings.
Read more →-SLN
Jul 11, 2023Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration 11 July 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”)
Silence Therapeutics announced they will receive a $4 million milestone payment from Hansoh Pharma after achieving two undisclosed preclinical milestones. This payment is part of a collaboration established in October 2021, which could yield up to $1.3 billion in future milestones. The company has previously achieved a $10 million milestone in a separate collaboration with AstraZeneca. Silence's efforts focus on advancing RNA interference technologies for treating diseases with significant unmet medical needs.
Read more →-SLN
May 4, 2023Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration 4 May 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced
Silence Therapeutics has achieved a significant milestone by receiving a $10 million payment from AstraZeneca for the nomination of the first product candidate under their siRNA collaboration. The companies began their collaboration in March 2020, targeting multiple therapeutic areas. AstraZeneca's payment reflects confidence in Silence's technology and potential. Industry leaders from both companies expressed optimism about future developments and continued success in addressing various diseases.
Read more →-SLN
May 1, 2023Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events 1 May 2023 LONDON, Silence Therapeu
Silence Therapeutics has successfully completed enrollment in its ALPACAR-360 phase 2 clinical trial of zerlasiran (SLN360), targeting patients with elevated lipoprotein(a) at risk for cardiovascular events. This swift enrollment process took less than four months, reflecting a strong market opportunity and effective team execution. Initial results from earlier studies indicate promising efficacy, with significant reductions in lipoprotein(a) levels observed. Expectation for topline data reporting is set for mid-2024, maintaining momentum in the company's clinical development pathway.
Read more →-SLN
Mar 28, 2023Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development - Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-en
Silence Therapeutics has appointed Dr. Steven Romano as the incoming Chief Medical Officer and Head of Research and Development, succeeding Dr. Giles Campion, who will retire by the end of the year. Dr. Romano, who has served on the Silence Board since 2019, brings over 25 years of pharmaceutical experience. He is expected to guide the company through its next phase of innovation using their proprietary mRNAi GOLD platform. His leadership is seen as crucial for advancing Silence's ongoing clinical activities and pursuing new opportunities.
Read more →-SLN
Jan 12, 2023Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates 12 January 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovati
Silence Therapeutics announced updates on its SLN360 and SLN124 clinical programs at the J.P. Morgan Healthcare Conference. The SLN360 program has dosed its first subjects in a Phase 2 study targeting high-risk atherosclerotic cardiovascular disease, with data expected in Q4 2023. Additionally, the SLN124 study for polycythemia vera is underway, with expectations for data from the Phase 1 multiple dose study in thalassemia patients also set for Q4 2023. The company's advancements signal significant progress in addressing high unmet medical needs within the respective indications.
Read more →-SLN
Nov 10, 2022to this Report on Form 6-K. Our actual results may differ materially from those contained in or implied by any forward-looking statements. Overview Silence Therapeutics plc ("we", "us", "our", "the Company" or "Silence")
Condensed consolidated income statement (unaudited) Three months ended Three months ended Nine months ended Nine months ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 000s (except per share information) ' 000s ' 000s ' 000s
Read more →-SLN
Nov 7, 2022Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting - Assessment showed participants who received a single d
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology com
Read more →-SLN
Sep 29, 2022Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia 29 September 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonu
Read more →-SLN
Aug 11, 2022Silence Therapeutics Announces Pricing of Underwritten Offering LONDON
Silence Therapeutics Announces Pricing of Underwritten Offering LONDON, August 11, 2022 Silence Therapeutics plc (Nasdaq: SLN) ( Silence ), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of
Read more →-SLN
May 16, 2022Silence Therapeutics plc Notice of Annual General Meeting 15. The AGM is an important opportunity for all shareholders to express their views by asking questions. Your participation in the AGM continues to be very import
Silence Therapeutics plc Notice of Annual General Meeting Notice of Annual General Meeting THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action to take, you should consult your stockbroker, solicitor, accountant or other a
Read more →-SLN
Apr 25, 2022Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration 25 April 2022 LONDON, Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration LONDON, Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of di
Read more →-SLN
Mar 17, 2022Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting - SLN360 reduced Lp(a) - a key gene
Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery,
Read more →-SLN
Mar 17, 2022Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501 Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first h
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501 Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 LONDON AND DUBLIN, Silence Therapeutics plc (
Read more →-SLN
Feb 22, 2022▲ +7.1%on this news
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer Mark Rothera steps down as President and CEO 21 February 2022 LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer Mark Rothera steps down as President and CEO LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interferi
Read more →-SLN
Feb 9, 2022▲ +6.8%on this news
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a) SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascul
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a) SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN36
Read more →-SLN
Dec 13, 2021New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases - Data presented at 2021 ASH annual meeting showed durable reductions in serum iron and transferrin saturation,
New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic aci
Read more →-SLN
Nov 26, 2021Silence Therapeutics plc: Update on AIM Delisting 26 November 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ( Silence or the Company ), a leader in the discovery, development and delivery of novel short i
Silence Therapeutics plc: Update on AIM Delisting LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ( Silence or the Company ), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of disea
Read more →-SLN
Nov 1, 2021Results of General Meeting 1 November 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ( Silence or the Company ), a leader in the discovery, development and delivery of novel short interfering ribonucleic a
Results of General Meeting LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ( Silence or the Company ), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant un
Read more →-SLN
Oct 21, 2021Silence Therapeutics Provides mRNAi GOLD Platform and Pipeline Updates at 2021 R&D Day - Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endog
Silence Therapeutics Provides mRNAi GOLD Platform and Pipeline Updates at 2021 R&D Day 21 October 2021, LONDON and NEW YORK -- Silence Therapeutics plc (AIM:SLN and Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siR
Read more →-SLN
Oct 15, 2021▲ +5.3%on this newsshared move
to this Report on Form 6-K. Our actual results may differ materially from those contained in or implied by any forward-looking statements. Overview Silence Therapeutics plc ( we , us , our , the Company or Silence ) is a
Condensed consolidated income statement (unaudited) Six months ended June 30, 2021 June 30, 2020 000s (except per share information) Revenue 5,845 1,146 Cost of sales (3,362) Gross profit 2,483 1,146 Research and development costs (15,625) (
Read more →-SLN
Oct 15, 2021▲ +5.3%on this newsshared move
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be held on 1 November 202
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be held on 1 November 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:S
Read more →-SLN
Aug 12, 2021Silence Therapeutics Reports Half-Year 2021 Results - Full enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a) - Silence to host R&D Day in
Silence Therapeutics Reports Half-Year 2021 Results LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of
Read more →-SLN
Jun 15, 2021Results of Annual General Meeting 15 June 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonu
Results of Annual General Meeting LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with signi
Read more →-SLN
Jun 7, 2021Silence Therapeutics to Present Data Highlighting Broad Therapeutic Potential for SLN124 at the European Hematology Association (EHA) 2021 Virtual Congress - Preclinical data at EHA support recently reported positive top
Silence Therapeutics to Present Data Highlighting Broad Therapeutic Potential for SLN124 at the European Hematology Association (EHA) 2021 Virtual Congress LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, developm
Read more →-SLN
May 25, 2021Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration Companies on-track to initiate work on five targets within the first three years of the c
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration Companies on-track to initiate work on five targets within the first three years of the collaboration LONDON, Silence Therapeutics plc, AIM:SLN a
Read more →-SLN
May 7, 2021Notice of Annual General Meeting 7 May 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucle
Notice of Annual General Meeting LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with signif
Read more →-SLN
Apr 29, 2021Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers - Data showed SLN124, an siRNA which targets TMPRSS6, was safe and effective in reducing plasma iron levels and had a
Silence Therapeutics Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucle
Read more →-SLN
Apr 29, 2021Silence Therapeutics Announces First Patient Dosed in GEMINI II Phase I Clinical Trial for SLN124 - First patient dosed in study evaluating Silence's wholly owned lead product candidate for thalassemia and myelodysplasti
Silence Therapeutics Announces First Patient Dosed in GEMINI II Phase I Clinical Trial for SLN124 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic ac
Read more →-SLN
Apr 28, 2021Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases 28 April 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "th
Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel
Read more →-SLN
Apr 19, 2021Purchase of American Depositary Shares and PDMR Dealings 19 th April 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of nov
Purchase of American Depositary Shares and PDMR Dealings LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment
Read more →-SLN
Mar 30, 2021Silence Therapeutics Reports Full-year 2020 Results Advancing clinical programmes; On-track for three phase 1 data readouts in 2021 30 March 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "
Silence Therapeutics Reports Full-year 2020 Results Advancing clinical programmes; On-track for three phase 1 data readouts in 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of no
Read more →-SLN
Feb 26, 2021Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases - Silence to receive $2 million research milestone payment - Silence is
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and
Read more →-SLN
Feb 17, 2021and proteins. Most people have some Lp (a) in their body, but about 1 in 5 people have high levels of Lp (a), because of a specific gene variation in their DNA. Most people are unaware if they have elevated Lp (a). Peopl
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a) LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel s
Read more →-SLN
Feb 4, 2021SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this " Agreement ") is made and entered into as of
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this "Agreement") is made and entered into as of February 4, 2021 by and among Silence Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the "Company"), and the Investors
Read more →-SLN
Jan 6, 2021Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer 6 January 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and deli
Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for
Read more →-SLN
Nov 16, 2020Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020 - Pre-clinical safety data show no adverse or off-target effects and tar
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and
Read more →-SLN
Nov 2, 2020Silence Therapeutics Appoints Dr. Marie Wikstr m Lindholm to its Executive Leadership Team - Dr. Lindholm's appointment reflects the Company's commitment to maximise the siRNA opportunity 2 November 2020 LONDON, Silence
Silence Therapeutics Appoints Dr. Marie Wikstr m Lindholm to its Executive Leadership Team LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (si
Read more →-SLN
Oct 8, 2020THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A R
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERE
Read more →-SLN
Sep 8, 2020Silence Therapeutics Provides Research and Development Update IND approval received for SLN360 to start dose escalation studies Dosing initiated for SLN124, the first dose of a Silence GalNAc-siRNA given to humans 8 Sept
Silence Therapeutics Provides Research and Development Update IND approval received for SLN360 to start dose escalation studies Dosing initiated for SLN124, the first dose of a Silence GalNAc-siRNA given to humans LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Sil
Read more →Competitive Position
How SLN ranks across every disease it competes inCompetitive Position is a premium feature
See how SLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial